Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiocentric Inotropic Optimization in Spinal Cord Injury
NCT07871643Phase 1Not yet recruiting
- Sponsor
- University of British Columbia
- Start
- Jun 2027
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dobutamine in spinal cord injury (SCI), sponsored by University of British Columbia. Primary endpoint: Mean Arterial Blood Pressure at 2.5 hours. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
dobutamine
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT07871643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07871643.